| Table of Contents (PDF)
|
Appendices Table of Contents
|
| Appendix A (PDF)
|
Abbreviations and Definitions
|
| Appendix B (PDF)
|
Glossary of Terms
|
| Appendix C (PDF)
|
Cytogenetic Assessments (Retired 2023)
|
| Appendix C (PDF)
|
Cytogenetic Assessments
|
| Appendix C (PDF)
|
CIBMTR Data Collection Forms
|
| Appendix D (PDF)
|
How to Distinguish Infusion Types
|
| Appendix D (PDF)
|
Unique ID Assignment Form (CRID), Form 2804
|
| Appendix E (PDF)
|
Public Health Authority (PHA) Status
|
| Appendix F (PDF)
|
Validation Ranges
|
| Appendix G (PDF)
|
Continuous Process Improvement (CPI) and Procedures for Non-Compliance
|
| Appendix H (PDF)
|
Summary of CIBMTR On-Site Data Audit Program
|
| Appendix H (PDF)
|
MDS & MPN Subtypes
|
| Appendix I (PDF)
|
Ethnicity and Race (Retired 2025)
|
| Appendix I (PDF)
|
Ethnicity and Race
|
| Appendix J (PDF)
|
Reporting Comorbidities
|
| Appendix K (PDF)
|
Key Fields
|
| Appendix L (PDF)
|
Karnofsky/Lansky Performance Status
|
| Appendix L (PDF)
|
Karnofsky/Lansky Performance Status (Retired 2025)
|
| Appendix M (PDF)
|
The Hematopoietic Cell Transplant-Co-morbidity Index (HCT-CI)
|
| Appendix M (PDF)
|
HCT Critical Data Fields
|
| Appendix N (PDF)
|
Response Evaluation Criteria in Solid Tumors (RECIST)
|
| Appendix O (PDF)
|
How to Distinguish Infusion Types
|
| Appendix O (PDF)
|
Cellular Therapy Critical Fields
|
| Appendix P (PDF)
|
Definition of Product
|
| Appendix Q (PDF)
|
United States Abbreviations
|
| Appendix R (PDF)
|
Cytogenetic Abbreviations and Terminology
|
| Appendix S (PDF)
|
Multiple Donor Chimerism
|
| Appendix T (PDF)
|
Pre-HCT Treatment for Lymphoma
|
| Appendix U (PDF)
|
Helpful Hints for Reporting Co-Existing Diseases
|
| Appendix V (PDF)
|
Multiple Myeloma - Defining What Baseline to Use When Determining the Best Response to HSCT
|
| Appendix W (DOC)
|
Tracking Disease Status for Multiple Myeloma
|
| Appendix Y (PDF)
|
Critical Fields
|
| Appendix Z (PDF)
|
Primary Disease and Disease Inserts Due
|
